From biomarker discovery and validation to trial design and label expansion, QIAGEN Real-World Insights (RWI) helps you bridge the gap between actionable insight and real-world action.
The majority of cancer patients today are diagnosed and treated outside the context of clinical research—that is, in the real world.
To improve the efficiency, efficacy, and cost of clinical trials, pharmaceutical companies are using real-world data at each stage of the drug development process.
QIAGEN’s Real-World Insights (RWI) portfolio combines robust real-world genomic data from over 200,000 cancer cases and advanced analytics to optimize biomarker discovery, maximize trial success, and shorten drug development timelines.
Oncology drug development can take up to 15 years, cost millions of dollars, and often relies on sparse data that doesn’t provide a full picture of a target patient population. But what if there’s a faster, safer, and more cost-effective way?
In the June 2020 issue of the Journal of Precision Medicine, Dr. Sheryl Elkin, CSO of QIAGEN Digital Insights, discusses the use of real-world genomic data to overcome the inefficiencies of drug development.
QIAGEN Real-World Insights (RWI) is a professional and personalized pharmaceutical development service dedicated to finding the fastest, most cost-effective route to move therapies from research to market. RWI provides access to real-world genomic data, helping pharmaceutical companies confidently answer critical questions, such as:
Dr. Anna Pokorska-Bocci of Debiopharm International shares her experience working with QIAGEN’s Real-World Insights team and how the customized analyses and offerings provided have enabled Debiopharm to accelerate drug development.
Do you have novel questions, hypotheses, and hurdles to overcome? Our team of scientists, bioinformaticists, and clinicians can help you strategize, customize, and deliver within your timeline.
From research to regulatory submission, we help you connect data to insight for faster drug discovery and optimized trial design
Choose the best biomarkers and cancer indications for your molecularly targeted therapies
Expand beyond the one biomarker, one drug paradigm with expert molecular profiling and drug-response analyses